BioXcel Presents Data on Potential Therapy at Prostate Cancer Foundation Retreat in D.C.

BioXcel Presents Data on Potential Therapy at Prostate Cancer Foundation Retreat in D.C.
BioXcel Therapeutics’ immuno-oncology candidate BXCL701 was shown to enhance the anti-tumor effects of immune checkpoint inhibitors in prostate models, according to an Oct. 5 poster session at the 24th Annual Prostate Cancer Foundation Scientific Retreat in Washington, D.C. The company reported recent findings from multiple studies showing that BXCL701 — a dipeptidyl peptidases (DPP) inhibitor —

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Lawrence Glickman says:

    Keep in mind I’m not a doctor nor do I have degrees in medical research. I have however been researching prostate cancer for over 15 years. The medical community often heralds the treatments of “Castrate Resistant Therapies” this usually means failure of the first round of therapies whatever they may be and it is usually a stop gap measure that while it extends life these drugs almost never “Cure” prostate cancer. Beware of getting to this point especially beware of hormone blockade treatments as they kill the easy target cancer cells and pave the way for “Castrate Resistant/Hormone/Resistant”cancer cells to proliferate. Recent studies have shown that cancer can actually “signal” other cancer cells which then triggers “evasive maneuvers” on the part of other cells. The best idea is get prostate cancer early and eliminate the problem using one of the new less invasive treatments.

Leave a Comment

Your email address will not be published. Required fields are marked *